Entera Bio (NASDAQ: ENTX) Secures $10 Million Investment from BVF Partners
Key Developments Entera Bio (NASDAQ: ENTX), a prominent developer of oral peptide therapeutics, has finalized a direct investment agreement with BVF Partners L.P., leading a private placement valued initially at $10 million. The company announced the execution of a securities purchase agreement that outlines the terms of this capital raise aimed at bolstering its development pipeline. This initial funding round carries potential for expansion, with total proceeds possibly reaching up…
